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Background
Transmission blocking vaccines (TBVs) target sexual
developÂ¬ment of the parasite within the mosquito and
aim to prevent transmission of malaria from one indivi-
dual to another. Antibodies raised against Pfs48/45,
Pfs230 Region C, PfHAP2, and Anopheles gambiae
Alanyl Aminopeptidase N1 (AgAPN1) proteins reduce
transmission i.e. have transmission blocking activity
[1-5]. Recombinant simian Adenovirus (AdC63 serotype)
and Modified Vaccinia Ankara (MVA) viral vectors have
been shown to induce high antibody titres to asexual
parasite antigens in animal studies [6].
Materials and methods
Protein sequences for each of the antigens were codon
optimised for expression in humans and cloned into
shuttle vectors, which were then recombined with the
parental virus and purified to obtain virus expressing
the antigen of interest. Mice were vaccinated with
AdC63 (i.m.), sera was taken after 2 weeks, and will be
followed by an MVA boost (i.d.) eight weeks after the
prime. Antibodies were assayed by a standardised
ELISA, and transmission blocking activity assessed using
a standardised membrane feeding assay (SMFA).
Conclusion
Induction of high antibody tires using this vaccine plat-
form could be used together with other control mea-
sures to achieve elimination and/or eradication of the
disease at a local or national level.
Author details
1Jenner Institute, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK.
2Division of Cell and Molecular Biology, Sir Alexander Fleming Building,
Imperia College London, Imperial College Road, London, SW7 2AZ, UK.
Published: 20 October 2010
References
1. Dinglasan RR, Kalume DE, Kanzok SM, Ghosh AK, Muratova O, Pandey A,
Jacobs-Lorena M: Disruption of Plasmodium falciparum development by
antibodies against a conserved mosquito midgut antigen. Proc Natl Acad
Sci USA 2007, 104:13461-6.
2. Chowdhury DR, Angov E, Kariuki T, Kumar N: A potent malaria
transmission blocking vaccine based on codon harmonized full length
Pfs48/45 expressed in Escherichia coli. PLoS One 2009, 4:e6352.
3. Bustamante PJ, Woodruff DC, Oh J, Keister DB, Muratova O, Williamson KC:
Differential ability of specific regions of Plasmodium falciparum sexual-
stage antigen, Pfs230, to induce malaria transmission-blocking
immunity. Parasite Immunol 2000, 22:373-80.
4. Blagborough AM, Sinden RE: Plasmodium berghei HAP2 induces strong
malaria transmission-blocking immunity in vivo and in vitro. Vaccine
2009, 27:5187-94.
5. Vermeulen AN, Ponnudurai T, Beckers PJ, Verhave JP, Smits MA,
Meuwissen JH: Sequential expression of antigens on sexual stages of
Plasmodium falciparum accessible to transmission-blocking antibodies
in the mosquito. J Exp Med 1985, 162:1460-76.
6. Draper SJ, Moore AC, Goodman AL, Long CA, Holder AA, Gilbert SC, Hill F,
Hill AV: Effective induction of high-titer antibodies by viral vector
vaccines. Nat Med 2008, 14:819-821.
doi:10.1186/1475-2875-9-S2-O22
Cite this article as: Kapulu et al.: Viral vectored transmission blocking
vaccines against Plasmodium falciparum. Malaria Journal 2010
9(Suppl 2):O22.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit 1Jenner Institute, University of Oxford, Roosevelt Drive, Oxford, OX3 7DQ, UK
Full list of author information is available at the end of the article
Kapulu et al. Malaria Journal 2010, 9(Suppl 2):O22
http://www.malariajournal.com/content/9/S2/O22
© 2010 Kapulu et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.